We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+48.57%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$2.32B
AUM Growth
+$490M
Cap. Flow
-$84M
Cap. Flow %
-3.62%
Top 10 Hldgs %
54.22%
Holding
73
New
11
Increased
23
Reduced
18
Closed
13

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$72.8M
2
AZN icon
AstraZeneca
AZN
+$70.9M
3
LLY icon
Eli Lilly
LLY
+$59M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$56.9M
5
ABBV icon
AbbVie
ABBV
+$38M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$139M
2
BSX icon
Boston Scientific
BSX
+$55.6M
3
AXSM icon
Axsome Therapeutics
AXSM
+$53.2M
4
ROIV icon
Roivant Sciences
ROIV
+$47.6M
5
DXCM icon
DexCom
DXCM
+$26M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIOA
26
BioAge Labs
BIOA
$968M
$30.3M 1.31%
2,293,788
– –
CELC icon
27
Celcuity
CELC
$4.03B
$29.9M 1.29%
299,417
+46,042
+18% +$3.78M
RYTM icon
28
Rhythm Pharmaceuticals
RYTM
$7B
$29.1M 1.25%
271,394
+24,428
+10% +$2.59M
CNTA
29
DELISTED
Centessa Pharmaceuticals
CNTA
$27.6M 1.19%
+1,104,274
New +$28M
SUPN icon
30
Supernus Pharmaceuticals
SUPN
$2.68B
$27.5M 1.19%
553,095
+176,029
+47% +$8.56M
INSM icon
31
Insmed
INSM
$23.2B
$27.3M 1.18%
156,801
+52,462
+50% +$9.57M
ALC icon
32
Alcon
ALC
$33.1B
$26.2M 1.13%
+332,520
New +$25.6M
RCUS icon
33
Arcus Biosciences
RCUS
$3.57B
$26.1M 1.13%
1,096,705
-125,558
-10% -$2.56M
DXCM icon
34
DexCom
DXCM
$27.6B
$25.1M 1.08%
378,219
-401,397
-51% -$26M
PHVS icon
35
Pharvaris
PHVS
$2.39B
$20.7M 0.89%
745,169
+5,293
+0.7% +$127K
NKTR icon
36
Nektar Therapeutics
NKTR
$2.39B
$18.5M 0.8%
438,630
+320,211
+270% +$17.9M
CMPX icon
37
Compass Therapeutics
CMPX
$373M
$18.1M 0.78%
3,365,446
+1,336,560
+66% +$6.17M
ROIV icon
38
Roivant Sciences
ROIV
$25.2B
$15.9M 0.69%
734,582
-2,414,688
-77% -$47.6M
ANAB icon
39
AnaptysBio
ANAB
$1.6B
$13.9M 0.6%
287,690
+33,422
+13% +$1.3M
GEHC icon
40
GE HealthCare
GEHC
$27.6B
$13.2M 0.57%
160,876
+9,791
+6% +$763K
EWTX icon
41
Edgewise Therapeutics
EWTX
$4.39B
$10.9M 0.47%
437,819
-82,421
-16% -$1.65M
EXAS
42
DELISTED
Exact Sciences
EXAS
$10.3M 0.44%
101,443
-263,557
-72% -$21.2M
IRON icon
43
Disc Medicine
IRON
$2.83B
$8.82M 0.38%
111,010
+97,457
+719% +$8.23M
AMLX icon
44
Amylyx Pharmaceuticals
AMLX
$2.05B
$6.37M 0.27%
+527,099
New +$7.16M
MASI
45
DELISTED
Masimo
MASI
$6.01M 0.26%
+46,201
New +$6.62M
QURE icon
46
uniQure
QURE
$2.68B
$4.22M 0.18%
176,513
+39,651
+29% +$1.53M
NXTC icon
47
NextCure
NXTC
$17.3M
$3.16M 0.14%
222,654
– –
WVE icon
48
Wave Life Sciences
WVE
$1.12B
$2.69M 0.12%
158,182
-12,761
-7% -$130K
XENE icon
49
Xenon Pharmaceuticals
XENE
$6.32B
$2.68M 0.12%
+59,900
New +$2.52M
EVMN
50
Evommune Inc
EVMN
$409M
$2.62M 0.11%
+153,320
New +$2.88M
1
2
3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2025 Portfolio in Review

As of Q4 2025, Sofinnova Investments held 73 positions worth $2.32B, up 27% from $1.83B the previous quarter. Its ten largest holdings account for 54% of the portfolio.

Sofinnova Investments withdrew a net $84M in Q4 2025, closing 13 positions and reducing 18 holdings. Its most notable exit was Gilead Sciences, an estimated $139M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 89% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Bristol-Myers Squibb worth $81.6M.

  • Sofinnova Investments's largest Q4 2025 buy was Bristol-Myers Squibb: 1,512,994 shares worth $81.6M.
  • Sofinnova Investments added most to AstraZeneca in Q4 2025, an estimated $70.9M increase.
  • Sofinnova Investments's biggest Q4 2025 reduction was Axsome Therapeutics, cutting an estimated $53.2M.
  • Sofinnova Investments fully exited Gilead Sciences in Q4 2025, selling an estimated $139M.
  • Sofinnova Investments's ten largest holdings make up 54% of its $2.32B portfolio in Q4 2025.
  • Sofinnova Investments opened 11 new positions and closed 13 in Q4 2025.
  • Sofinnova Investments's portfolio value rose 27% quarter-over-quarter to $2.32B.

Based on Sofinnova Investments's 13F filing for Q4 2025, filed 13 Feb 2026.